ESG News For Mount Sinai Medical Center

First patient dosed in Phase 2 trial for PIKTOR strategy, dual PI3K/AKT/mTOR pathway inhibitors with paclitaxelBuilds on Phase 1b study that demonstrated 80% ORR in Endometrial cancerPartnering with The GOG Foundation, Inc. (GOG-F), a not-for-profit organization with the mission of transforming the standard of care in gynecologic oncology